The metabolism of Clindamycin can be decreased when combined with Clarithromycin. Clindamycin may increase the neuromuscular blocking activities of Tubocurarine. The metabolism of Clindamycin can be decreased when combined with Rucaparib. The metabolism of Clindamycin can be decreased when combined with Venlafaxine. Clindamycin may increase the neuromuscular blocking activities of Mecamylamine. The serum concentration of Ibrutinib can be increased when it is combined with Clindamycin. The serum concentration of Clindamycin can be decreased when it is combined with Vemurafenib. The metabolism of Clindamycin can be decreased when combined with Voriconazole. Clindamycin may increase the neuromuscular blocking activities of Decamethonium. The therapeutic efficacy of Clindamycin can be decreased when used in combination with Sarilumab. The risk or severity of adverse effects can be increased when Pergolide is combined with Clindamycin. The risk or severity of adverse effects can be increased when Nicergoline is combined with Clindamycin. Clindamycin may increase the neuromuscular blocking activities of Atracurium besylate. The serum concentration of Clindamycin can be increased when it is combined with Aprepitant. The metabolism of Clindamycin can be decreased when combined with Lopinavir. The serum concentration of Conivaptan can be increased when it is combined with Clindamycin. The metabolism of Clindamycin can be decreased when combined with Fluconazole. The risk or severity of adverse effects can be increased when Lisuride is combined with Clindamycin. The metabolism of Clindamycin can be decreased when combined with Atomoxetine. The serum concentration of Clindamycin can be decreased when it is combined with Siltuximab. The serum concentration of Clindamycin can be increased when it is combined with Simeprevir. The serum concentration of Clindamycin can be increased when it is combined with Fosaprepitant. Clindamycin may increase the neuromuscular blocking activities of Succinylcholine. The serum concentration of Clindamycin can be increased when it is combined with Ivacaftor. Clindamycin may increase the neuromuscular blocking activities of Domoic Acid. The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Clindamycin. The serum concentration of Clindamycin can be increased when it is combined with Stiripentol. Clindamycin may increase the neuromuscular blocking activities of Cisatracurium. The metabolism of Clindamycin can be decreased when combined with Verapamil. The serum concentration of Clindamycin can be increased when it is combined with Ceritinib. The metabolism of Clindamycin can be decreased when combined with Olaparib. The metabolism of Clindamycin can be decreased when combined with Isavuconazonium. The metabolism of Clindamycin can be decreased when combined with Saquinavir. The metabolism of Clindamycin can be decreased when combined with Imatinib. Clindamycin may increase the neuromuscular blocking activities of Gallamine Triethiodide. The serum concentration of Clindamycin can be decreased when it is combined with Mitotane. The serum concentration of Clindamycin can be increased when it is combined with Osimertinib. The metabolism of Clindamycin can be decreased when combined with Clemastine. The metabolism of Clindamycin can be decreased when combined with Lovastatin. The serum concentration of Clindamycin can be increased when it is combined with Luliconazole. The therapeutic efficacy of Clindamycin can be decreased when used in combination with Erythromycin. Clindamycin may increase the neuromuscular blocking activities of Pancuronium. The serum concentration of Clindamycin can be increased when it is combined with Palbociclib. The serum concentration of Pravastatin can be increased when it is combined with Clindamycin. The metabolism of Clindamycin can be increased when combined with Phenytoin. The metabolism of Clindamycin can be decreased when combined with Itraconazole. The metabolism of Clindamycin can be decreased when combined with Dihydroergotamine. The metabolism of Clindamycin can be decreased when combined with Ticlopidine. Clindamycin may increase the neuromuscular blocking activities of Pipecuronium. The metabolism of Clindamycin can be increased when combined with Rifampicin. The risk or severity of adverse effects can be increased when Cabergoline is combined with Clindamycin. The metabolism of Clindamycin can be decreased when combined with Ketoconazole. The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Clindamycin. Clindamycin may increase the neuromuscular blocking activities of Metocurine. The serum concentration of Ubidecarenone can be increased when it is combined with Clindamycin. The serum concentration of Clindamycin can be increased when it is combined with Dasatinib. The serum concentration of Pitavastatin can be increased when it is combined with Clindamycin. The metabolism of Clindamycin can be decreased when combined with Clotrimazole. Clindamycin may increase the neuromuscular blocking activities of Rapacuronium. The serum concentration of Fluvastatin can be increased when it is combined with Clindamycin. Clindamycin may increase the neuromuscular blocking activities of Mivacurium. The metabolism of Clindamycin can be decreased when combined with Idelalisib. The risk or severity of adverse effects can be increased when Methylergometrine is combined with Clindamycin. The metabolism of Clindamycin can be decreased when combined with Doxycycline. The metabolism of Clindamycin can be decreased when combined with Amiodarone. The metabolism of Clindamycin can be decreased when combined with Diltiazem. The metabolism of Clindamycin can be decreased when combined with Isradipine. The risk or severity of adverse effects can be increased when Ergonovine is combined with Clindamycin. The metabolism of Clindamycin can be decreased when combined with Boceprevir. The metabolism of Clindamycin can be increased when combined with Rifabutin. The serum concentration of Bosutinib can be increased when it is combined with Clindamycin. The serum concentration of Clindamycin can be decreased when it is combined with Bosentan. The metabolism of Clindamycin can be decreased when combined with Ranolazine. The metabolism of Clindamycin can be decreased when combined with Telithromycin. The metabolism of Clindamycin can be decreased when combined with Fosamprenavir. The serum concentration of Mevastatin can be increased when it is combined with Clindamycin. The serum concentration of Clindamycin can be decreased when it is combined with Enzalutamide. The metabolism of Clindamycin can be decreased when combined with Telaprevir. Kaolin can cause a decrease in the absorption of Clindamycin resulting in a reduced serum concentration and potentially a decrease in efficacy. The metabolism of Clindamycin can be decreased when combined with Posaconazole. The serum concentration of Clindamycin can be decreased when it is combined with St. John's Wort. The metabolism of Clindamycin can be decreased when combined with Dronedarone. The risk or severity of adverse effects can be increased when Metergoline is combined with Clindamycin. Clindamycin may increase the neuromuscular blocking activities of Doxacurium chloride. The metabolism of Clindamycin can be decreased when combined with Indinavir. The serum concentration of Rilpivirine can be increased when it is combined with Clindamycin. The metabolism of Clindamycin can be decreased when combined with Nefazodone. The metabolism of Clindamycin can be decreased when combined with Darunavir. The metabolism of Clindamycin can be decreased when combined with Nilotinib. The metabolism of Clindamycin can be increased when combined with Nevirapine. The serum concentration of Clindamycin can be increased when it is combined with Mifepristone. The metabolism of Clindamycin can be decreased when combined with Ziprasidone. Clindamycin may increase the neuromuscular blocking activities of Cisatracurium besylate. The risk or severity of adverse effects can be increased when Clindamycin is combined with Atorvastatin. The metabolism of Clindamycin can be increased when combined with Pentobarbital. The metabolism of Clindamycin can be decreased when combined with Sulfisoxazole. The serum concentration of Clindamycin can be decreased when it is combined with Tocilizumab. The risk or severity of adverse effects can be increased when Bromocriptine is combined with Clindamycin. The metabolism of Clindamycin can be decreased when combined with Atazanavir. Clindamycin may increase the neuromuscular blocking activities of Pyrantel. The metabolism of Clindamycin can be decreased when combined with Bortezomib. The metabolism of Clindamycin can be decreased when combined with Cobicistat. The metabolism of Clindamycin can be increased when combined with Primidone. The serum concentration of Clindamycin can be decreased when it is combined with Dabrafenib. The metabolism of Clindamycin can be increased when combined with Phenobarbital. The serum concentration of Simvastatin can be increased when it is combined with Clindamycin. The metabolism of Clindamycin can be decreased when combined with Delavirdine. Clindamycin may increase the neuromuscular blocking activities of Neosaxitoxin. The metabolism of Clindamycin can be increased when combined with Fosphenytoin. The serum concentration of Clindamycin can be decreased when it is combined with Deferasirox. The metabolism of Clindamycin can be increased when combined with Rifapentine. The metabolism of Clindamycin can be increased when combined with Carbamazepine. Clindamycin may increase the neuromuscular blocking activities of Metocurine Iodide. The risk or severity of adverse effects can be increased when Ergotamine is combined with Clindamycin. The metabolism of Clindamycin can be decreased when combined with Crizotinib. The serum concentration of Tolvaptan can be increased when it is combined with Clindamycin. The serum concentration of Clindamycin can be increased when it is combined with Netupitant. The risk or severity of adverse effects can be increased when Methysergide is combined with Clindamycin. The metabolism of Clindamycin can be decreased when combined with Cyclosporine. The metabolism of Clindamycin can be increased when combined with Lumacaftor. Clindamycin may increase the neuromuscular blocking activities of Rocuronium. Clindamycin may increase the neuromuscular blocking activities of Vecuronium. The metabolism of Clindamycin can be decreased when combined with Nelfinavir. The serum concentration of Clindamycin can be increased when it is combined with Fusidic Acid. The metabolism of Clindamycin can be decreased when combined with Fluvoxamine. The serum concentration of Rosuvastatin can be increased when it is combined with Clindamycin. The metabolism of Clindamycin can be decreased when combined with Sildenafil. The serum concentration of Cerivastatin can be increased when it is combined with Clindamycin.